Some Specific Chromosomal Aberrations of Hematologic Malignancies in 80 Iranian Population

Yaghmaie M,1 Gerayeli N,1 Ghaffari SH,1 Ghavamzadeh A,1 Tootian SM2

1Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences
2Iranian Blood Transfusion Organization, Tehran, Iran

Corresponding Author: Seyed Hamidollah Ghaffari, PhD
Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Kargar Ave., Tehran, Iran
Phone Number: +98 21 84902638
Fax Number: +98 21 88004140
Email: shghaffari2000@yahoo.com

Abstract

Introduction: Most of the hematologic malignancies are heterogenous with regard to morphology, immunophenotype, and genetic rearrangements. Multiple recurrent chromosomal aberrations have been identified by conventional cytogenetic analysis, which is now widely recognized as one of the most important diagnostic and prognostic determinants in these patients.

Patients and Methods: Bone marrow samples were obtained from 80 patients with different hematologic malignancies. These consisted of 43 CML cases, 27 AML, 9 ALL and 1 MDS. In each case, cells were cultured and conventional cytogenetic analysis was performed.

Results: Among the 80 subjects, 53(66%) were abnormal and 27(34%) showed apparently normal karyotype. The various aberrations in abnormal cases were t(9; 22)(q34;q11) in 43 CML (100%), Monosomy Y in 2 CML (4.6%), monosomy 7 in 1 CML (2.4%), trisomy 8 and t(15;17)(q22;q21) in 2 AML case(7.4%), t(8;21)(q22;q22) in 1 AML (3.7%) and complex karyotype in 2 CML, 1 AML, 1 ALL and 1 MDS (6%). Apart from these, some novel chromosomal abnormalities were observed in our study population.

Conclusion: The difference in the frequency of clonal chromosomal aberrations is probably the result of the applied methods for chromosome preparation and often very poor morphologic chromosome appearance, making the identification of finer structural abnormalities more difficult. Furthermore, ongoing cytogenetic studies are warranted in larger groups of hematologic malignancies to identify newly acquired chromosomal aberrations that may aid in cloning novel genes involved in the neoplastic process, ultimately helping in the development of targeted therapeutic drugs.

Keyword: Chromosomal aberration, Hematologic Malignancy, Karyotype

Received: 28, June, 2009
Accepted: 20, Sep., 2009

Introduction

Cytogenetic analysis of malignant hematological disease is an important methodology used by clinicians and researchers, as observations of clonal chromosomal abnormalities have been shown to have both diagnostic and prognostic significance. Conventional cytogenetic analysis of chromosome abnormalities in hematologic malignancies is hampered by the low mitotic index and poor quality of metaphases. Either bone marrow or peripheral blood cells may be used to prepare chromosome spreads for cytogenetic analysis. The identification of these nonrandom chromosomal abnormalities in association with specific hematological diseases laid the foundation for the clinical significance of cytogenetic analysis.(1, 2, 3) Recurring chromosome abnormalities are important prognostic indicators for the hematologist.(4) Cytogenetic anomalies identified in patients with hematologic malignancies are among the most important independent prognostic factors and are currently used to plan for different types of therapy. Acquired chromosomal abnormalities, structural or numerical, are detected in malignant bone marrow cells in more than 75% of patients with hematologic malignancies, with an increasing incidence due to the application of complementary detection methods provided by molecular cytogenetics.(5) The accuracy of cytogenetic analysis has been significantly improved over the last 30 years due to
### Table- 1. FAB subtypes and chromosomal abnormalities of the patients with Complex Karyotype

<table>
<thead>
<tr>
<th>FAB Type</th>
<th>Karyotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>CML</td>
<td>48,XY,t(9;22)(q34;q11);+8,+Ph[18]/47XY,t(9;22)(q34;q11);+8[78]/46,XY[5]</td>
</tr>
<tr>
<td>MDS</td>
<td>47,XX,+8[3]/47,XX,+8,par inv(17)(p11,p13)[8]/46,XX[9]</td>
</tr>
<tr>
<td>ALL</td>
<td>46,XY,i(8)(q10),del(9)(p22)[14]/46,XY[1]</td>
</tr>
</tbody>
</table>

**FAB**: French-American-British, **CML**: Chronic Myelogenous Leukemia, **MDS**: Myelodysplastic Syndrome, **ALL**: Acute Lymphoblastic Leukemia, **AML**: Acute Myelogenous Leukemia.

### Table- 2. Chromosomal abnormalities in the 80 patients successfully karyotyped

<table>
<thead>
<tr>
<th>Parameter</th>
<th>No. of patients</th>
<th>CML</th>
<th>AML</th>
<th>ALL</th>
<th>MDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karyotypes</td>
<td>80</td>
<td>43</td>
<td>27</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Normal</td>
<td>27</td>
<td>20</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal</td>
<td>53</td>
<td>43</td>
<td>7</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Single</td>
<td>42</td>
<td>37</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double</td>
<td>6</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Complex</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Monosomy Y</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monosomy 7</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(15;17)(q22;q21)</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>trisomy 8</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(9;22)(q34;q11)</td>
<td>43</td>
<td>42</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Discussion

Technical advances regarding culture methodology and banding techniques.(6, 7)

High resolution chromosome analysis, introduced in 1976 by Yunis, involves synchronization of dividing cells in prophase or prometaphase, resulting in longer chromosomes with multiple bands.(8) At this level of resolution (over 600 bands per chromosome), structural abnormalities of 3-5Mb of DNA can be detected, while alterations smaller than 3Mb and translocations involving telomeric regions are extremely difficult to identify.(9) Furthermore, high resolution chromosome analysis is labor-intensive and has the limitation of the inconsistency of band resolution. The possible presence of multiple abnormal clones, the poor quality of metaphases and the low mitotic index associated with the disease have been widely recognized as the major problems associated with applying conventional cytogenetic analysis to hematologic malignancies.

### Patients and Methods

A total of 4 ml of bone marrow (BM) aspirates were obtained from 80 patients with different hematological malignancies who visited the Department of Hematology- Oncology and Stem Cell Transplantation at Shariati Hospital, from 2006 to 2008. All the cell cultures and cytogenetic analysis were performed in our center with the support of grants from the Tehran University of Medical Sciences.

Bone marrow cells were cultured for 24 hours in RPMI 1640 supplemented with 20% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and streptomycin. After a 24-hour incubation, colcemid was added at a final concentration of 0.1 µg/ml for 20 minutes. Then, the cells were treated with hypotonic KCl (0.075 M) for 12–15 minutes and fixed with methanol/acetic acid (3:1). Metaphase chromosomes were banded using the conventional GTG banding technique and karyotyped according to the International System for Human Cytogenetic Nomenclature (ISCN).(10) Each time, the 10 to 20 chromosomal spread was analyzed even if the quality was not optimal; from these, twenty metaphases were analyzed with Leica software whenever possible to demonstrate the clonal nature of the aberrations. A karyotype was considered complex if there was an involvement of three or more chromosomes.

### Results

We report herein cytogenetic studies on 80 Iranian patients with hematological malignancy; 43 CML, 27 AML, 9 ALL, and one MDS case. Of these, 51 (60.7%) were males and 29 (39.5%) were females (Figure- 1). The age distribution was in the range of 3-70 years and the mean age was 40 years. Patients were divided into different ranges of disease and age as shown in Figure- 2. Of the 80 patients, which were successfully karyotyped, 27 (34%) had normal karyotype and 53 patients (66%) had a
Chromosomal aberrations (Figure- 4). The most frequent chromosomal abnormalities were t(9;22)(q34;q11) in 43 CML (100%). Monosomy Y was found in 2 CML (4.6%) and in 2 AML (7.4%), monosomy 7 in 1 CML (2%), trisomy 8 in 2 CML (4%), 1 AML (3.5%) and 1 MDS. Chromosomal translocation of t(15;17)(q22;q21) was observed in 2 AML (7%) cases, t(8;21)(q22;q22) in 1 AML (3.7%) and complex karyotypes in 2 CML (4%), 1 AML (7%), 1 ALL (11%) and 1 MDS. Some chromosomal abnormalities of the patients with complex karyotype are shown in Table-1. In addition to these non-random chromosomal abnormalities, some rare abnormalities were also encountered (Table-2). Karyotyping results of some chromosomal aberration in our patients are shown in Figures-5 A, B, C, D.

Discussion

For the past three decades, cytogenetic studies of hematological disorders indicate that each and every case is equally and critically important. There are an increasing numbers of balanced rearrangements associated with distinct cases and clinical features, suggesting that chromosomal abnormalities reflect basic differences in leukemia biology. Furthermore, clonal cytogenetic abnormalities are one of the most important factors in predicting clinical outcomes in leukemia and are used to guide risk-adapted treatment strategies.(11) In this study, 52.5% of the patients had at least one chromosome abnormality. The frequency of chromosomal aberrations reported in the literature is extremely variable, ranging from 51 to 90%.(12,13,14,15) This difference in the frequency of clonal chromosomal aberrations is probably the result of the applied methods for chromosome preparation and often very poor morphologic chromosome appearance, making the identification of finer structural abnormalities more difficult. According to the double and complex chromosomal aberration, we found 7.5% of our patients with double and 6.5% with more than two chromosomal aberrations. We also found some recurring chromosomal aberrations like trisomy 8 in two CML, one AML and one MDS of our patients. From 27 AML patients that were successfully karyotyped, seven patients had abnormal karyotypes. The t(15;17) abnormality was identified in 7.4% of our AML patients. In some other reports, however, t(15;17) is identified in 11–15% of AML.(12,13,16) From 43 CML patients that had been karyotyped, we found 43 abnormal karyotypes. From 43 CML
patients with abnormal karyotypes all had Philadelphia chromosome but only 4.6% of them had complex karyotypes with trisomy 8 and monosomy Y. One ALL patient also had Philadelphia chromosome. We also showed one MDS patient with +8 and inv(17). This following cytogenetic aberration was reported in 15-20% of MDS and 5-10% treatment-related MDS.(10)

In conclusion, we are reporting some of the incidence of the chromosomal abnormalities which vary considerably among our patients with different hematological malignancies, from the time we have set up our own cytogenetic analysis.

Future large, prospective, and randomized trials are warranted to provide stronger evidence regarding the clinical relevance of chromosomal aberrations and its molecular pathogenesis.

References
13. Grimwade D, Walker H, Oliver F, et al. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of

